Most people find that symptoms peak around weeks two to four of each new dose level and then gradually improve
This is likely related, at least in part, to the magnitude of weight loss following bariatric/metabolic surgery
In the United States, the FDA has not approved BPC-157 for any indication, and it cannot legally be sold as a dietary supplement or as a finished pharmaceutical product
In phase 3 trials, maximal dose retatrutide demonstrated 29% placebo-adjusted weight loss at 68 weeks (albeit with higher discontinuation rates than semaglutide and tirzepatide)
Of course, exercise is not a substitute for a healthy diet
branded medications carry extensive clinical trial data, while compounded formulations from licensed 503A pharmacies offer flexibility and potentially lower out-of-pocket costs